JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

Search

Dr Reddy's Laboratories Ltd-ADR

Gesloten

SectorGezondheidszorg

13.8

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

13.77

Max

13.86

Belangrijke statistieken

By Trading Economics

Inkomsten

-1.8B

14B

Verkoop

392M

85B

K/W

Sectorgemiddelde

17.909

34.393

Dividendrendement

0.66

Winstmarge

16.496

Werknemers

27,811

EBITDA

-622M

25B

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+17.39% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.66%

2.54%

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-476M

12B

Vorige openingsprijs

13.8

Vorige sluitingsprijs

13.8

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Dr Reddy's Laboratories Ltd-ADR Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

23 jul 2025, 17:49 UTC

Winsten

Dr. Reddy's Labs 1Q Global Generics Revenue $75.62B >RDY

23 jul 2025, 17:48 UTC

Winsten

Dr. Reddy's Labs 1Q EPS $17.02 >RDY

23 jul 2025, 17:48 UTC

Winsten

Dr Reddy's Labs 1Q Rev $85.45B >RDY

9 mei 2025, 18:56 UTC

Winsten

Dr Reddy's Laboratories 4Q EPS INR19.11 >RDY

9 mei 2025, 18:56 UTC

Winsten

Dr Reddy's Laboratories 4Q Rev INR85.06B >RDY

23 jan 2025, 17:46 UTC

Winsten

Dr. Reddy's 3Q Net Attributable to Equity Holders of Parent Company INR14.13B

23 jan 2025, 17:42 UTC

Winsten

Dr. Reddy's 3Q Rev INR83.59B

5 nov 2024, 11:01 UTC

Winsten

Dr. Reddy's Laboratories 1H Rev INR156.89B Vs. INR136.19B >RDY

5 nov 2024, 11:00 UTC

Winsten

Dr. Reddy's Laboratories 1H Net INR26.47B Vs. Net INR28.825B >RDY

5 nov 2024, 10:57 UTC

Winsten

Dr. Reddy's Laboratories 2Q Net INR12.55B Vs. Net INR14.80B >RDY

5 nov 2024, 10:57 UTC

Winsten

Dr. Reddy's Laboratories 2Q Rev INR80.16B Vs. INR68.80B >RDY

Peer Vergelijking

Prijswijziging

Dr Reddy's Laboratories Ltd-ADR Prognose

Koersdoel

By TipRanks

17.39% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 16.2 USD  17.39%

Hoogste 16.9 USD

Laagste 15.5 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Dr Reddy's Laboratories Ltd-ADR - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

2 ratings

1

Buy

1

Hold

0

Sell

Technische score

By Trading Central

N/A / 13.84Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Weak Bullish Evidence

Lange Termijn

Weak Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Dr Reddy's Laboratories Ltd-ADR

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.